Evaluation the Fibroblast Growth Factor-23 Role with Some Biochemical Parameters in Heart Diseases Patients

Abstract

Heart disease is a chronic disease directly related to chronic diseases all over the world, so this study aims to evaluate the role of the protein fibroblast growth factor - 23 fibroblast growth factor - 23 with some biochemical progress in the health of the blood of patients with myocardial infarction and patients with atherosclerosis. The study included 60 artistic drawings of patients with myocardial infarction and 30 charts of patients with atherosclerosis) whose ages ranged from 35 to 65 years, and discovered 30 artistic drawings of healthy people in the same age group, and controlled from the reviewers of Azadi Teaching Hospital in Kirkuk Governorate by diagnosis with ultrasound devices and planning of laboratory medical tests that were allocated by the factors not including the period in the period from 2/15/2022 to 4/29/2023. The results show a significant increase in the concentration of fibroblast growth factor-23 in the two groups of myocardial infarction patients and atherosclerosis patients compared to healthy controls, and a significant increase in the achievement of the enzyme creatine kinase in myocardial infarction patients compared to healthy controls. The presence of high results in the total ranges, diverse proteins, target groups and very broad target proteins in the high-impact dragon horns in the two groups of patients compared to healthy controls. The results show a significant decrease in the protein level for myocardial infarction patients compared to healthy controls, while the group did not indicate any significant difference. Due to the absence of a significant difference in the level of membership subscriptions in the two groups compared to healthy controls. The results show a significant decrease in the level of glutathione and other significant decreases in the level of nitric oxide in the two groups of patients compared to healthy controls.